Blueprint Medicines Corporation (BPMC)
| Market Cap | 5.67B |
| Revenue (ttm) | 793.74M |
| Net Income (ttm) | 313.88M |
| Shares Out | 54.53M |
| EPS (ttm) | 5.59 |
| PE Ratio | 16.60 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 3 |
| Last Price | $92.80 |
| Previous Close | $98.79 |
| Change ($) | -5.99 |
| Change (%) | -6.06% |
| Day's Open | 98.45 |
| Day's Range | 92.52 - 99.66 |
| Day's Volume | 412,598 |
| 52-Week Range | 43.29 - 125.61 |
Blueprint Medicines' (BPMC) earnings beat estimates in the fourth quarter of 2020 while revenues meet the same. Shares up.
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 2.55% and -1.10%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the...
Shares of Blueprint Medicines (NASDAQ:BPMC) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share fell 13.33% over the past year to ($1.53), which beat the...
CAMBRIDGE, Mass., Feb. 17, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results and provided a business update for the fourth quarter and full ye...
CAMBRIDGE, Mass., Feb. 5, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immu...
Blueprint Medicines (BPMC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near ...
3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic
CAMBRIDGE, Mass., Jan. 11, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced leadership transitions for the company's research and development organization. E...
We highlight a few biotech companies, which outperformed the sector in 2020 and are likely to witness a winning run in the near term.
CAMBRIDGE, Mass., Jan. 5, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immu...
Blueprint Medicines' (BPMC) lead drug, Ayvakit, approved for PDGFRA Exon 18 mutant GIST is off to a solid start. The company's second drug, Gavreto, gets approved for two types of cancer indic...
CAMBRIDGE, Mass., Dec. 4, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immu...
The FDA grants accelerated nod to Blueprint Medicines' (BPMC) Gavreto for treating patients with advanced/metastatic RET-altered thyroid cancer.
CAMBRIDGE, Mass., Dec. 1, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immu...
Investors are hyper-focused on COVID-19 right now, but once vaccines for the virus have been approved, other healthcare stocks will start to zoom forward.
Keeping this in mind, let's analyze whether Blueprint Medicines Corporation (NASDAQ:BPMC) is a good investment right now by following the lead of some of the best investors in the world and pi...
CAMBRIDGE, Mass., Nov. 3, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immu...
Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q3 2020 Results - Earnings Call Transcript
Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q3 2020 Results - Earnings Call Transcript
Blueprint Medicines' (BPMC) both bottom and the top line trump estimates in Q3. Ayvakit's sales rise sequentially.
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 71.96% and 31.67%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for t...
Marc Schneidman's Aquilo Capital Management is a San Francisco-based, healthcare-focused long/short hedge fund that was founded in 2010. The fund uses CIO Schneidman's 20 years of industry exp...
Blueprint Medicines' (BPMC) lead drug Ayvakyt/Ayvakit approved for PDGFRA Exon 18 mutant GIST is off to a solid start. The company's efforts to expand the drug's label are promising as well.
Blueprint European Approval, And Other News: The Good, Bad And Ugly Of Biopharma
Blueprint Medicines' (BPMC) Ayvakyt gains a conditional marketing approval from the European Commission for unresectable/metastatic gastrointestinal stromal tumors harboring the PDGFRA D842V m...
CAMBRIDGE, Mass., Sept. 25, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer im...
Blueprint Medicines (BPMC) reports positive top-line results from the EXPLORER and the PATHFINDER studies, which are evaluating Ayvakit for patients with advanced systemic mastocytosis. Shares...
Blueprint Medicines on Tuesday reported positive test results for its treatment for a potentially fatal rare disease, sending BPMC stock to an eight-month high extending beyond a buy zone. The...
CAMBRIDGE, Mass., Sept. 20, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer im...
PITTSBURGH, Sept. 14, 2020 /PRNewswire/ -- PANTHERx® Rare Pharmacy announces that it has been selected by Blueprint Medicines as a limited distribution partner for new drug GAVRETO™ (pralsetin...
Here's what investors need to know about this successful yet underappreciated cancer drug developer.
CAMBRIDGE, Mass., Sept. 9, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immu...
CAMBRIDGE, Mass., Sept. 4, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer imm...
Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock?
Blueprint Medicines (BPMC) posts a wider-than-expected loss but revenues beat estimates in the second quarter of 2020.
Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q2 2020 Results - Earnings Call Transcript
Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q2 2020 Results - Earnings Call Transcript
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -9.62% and 10.36%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the st...
CAMBRIDGE, Mass., July 24, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer imm...
Blueprint Medicines CEO on $1.7 billion cancer drug partnership with Roche
Blueprint Medicines has partnered with Roche on pralsetinib, a cancer drug.
Roche is licensing commercial rights to Blueprint Medicines RET-inhibitor pralsetinib.
Blueprint Medicines (BPMC) signs a contract with Roche to commercialize pralsetinib for treating patients with RET-fusion NSCLC, RET-mutant MTC, other thyroid cancers and other solid tumors.
Blueprint Medicines Corp. (NASDAQ: BPMC) announced early on Tuesday that it had entered into a global collaboration with pharmaceutical giant Roche in which it may receive up to $1.7 billion.
Shares of Blueprint Medicines Corp. BPMC, -2.93% gained 8.3% in premarket trading on Tuesday, the day after the company announced a deal with Roche Holding AG ROG, -1.66% to develop and commer...
CAMBRIDGE, Mass., July 14, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer imm...
Blueprint Medicines (BPMC) files an NDA to the FDA for pralsetinib to treat patients with advanced/metastatic RET mutant medullary thyroid cancer and RET fusion-positive thyroid cancers. Stock...
CAMBRIDGE, Mass., July 1, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immu...
CAMBRIDGE, Mass., June 29, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer imm...
CAMBRIDGE, Mass., June 6, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immu...
Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock?
Blueprint Medicines and Deciphera Pharmaceuticals were going toe-to-toe developing treatments for this rare cancer. Investors can now call the winner.
About BPMC
Blueprint Medicines Corporation, a precision therapy company, develops transformative medicines for people with cancer and hematologic disorders, and multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy in the United States and Europe. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and fisogatinib, an o... [Read more...]
| Industry Biotechnology | IPO Date Apr 30, 2015 |
| CEO Jeffrey Albers | Employees 429 |
| Stock Exchange NASDAQ | Ticker Symbol BPMC |
Analyst Forecasts
According to 14 analysts, the average rating for BPMC stock is "Buy." The 12-month stock price forecast is 117.29, which is an increase of 26.39% from the latest price.